October 2020: Remdesivir gets FDA approval.
World Health Organisation fails to warn of death rates.

The World Health Organisation (WHO) was involved in the ebola trials in 2019, in which remdesivir resulted in a 53% mortality rate.

WHO undertook a drug trial from 22 March 2020 to 4 October 2020 of11,330 adults. The drugs trialled included remdesivir, hydroxychloroquine, lopinavir (fixed-dose combination with Ritonavir) and Interferon-β1a. The results were published in October 2020.

The report clearly shows deaths resulted with remdesivir, however WHO, refused to inform the world that remdesivir caused death and instead only made a message that remdesivir had not effect. On 22 October 2020, US News published WHO’s statement, which said,

“the drug had little or no effect in preventing death from COVID-19 or reducing time in hospital”.

WHO sent a deceptive message by only presenting one side of information - that remdesivir did not offer any benefits. It refused to inform that it resulted in death.